Get started
Author

J. David Beatty

OpenAlex ID: A5065115288
Clinical Value of Carcinoembryonic Antigen
1979 · J. David Beatty · Archives of Surgery · 62
Correction: Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers with Potential for Prognosis and Early Detection
2010 · Michèl Schummer, Ann Green, et al. · PLoS ONE · 5
Supplementary Tables 1 - 4 from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
Supplementary Figure Legends from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
Supplementary Tables 1 - 4 from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
PDF
Supplementary Methods from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
Supplementary Figures 1 - 4 from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
Supplementary Methods from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
PDF
Supplementary Figure Legends from JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors
2023 · Chris P. Miller, Jason D. Thorpe, et al.
PDF
Works count: 9
Citation count: 67
H-index: 2
I10-index: 1
Year
Topic
Type